Loading...
01/11 03:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A reveal strong financial performance with an 84% revenue increase and a 58% gross margin. Management is optimistic about growth, especially in Q4, and is implementing flexible sales models to overcome capital constraints. The company is focused on innovation and market expansion, particularly in pharma and biotech. Despite some unclear responses, the overall sentiment is positive, supported by strategic product launches and a solid cash position. The stock price is likely to experience a positive movement in the next two weeks.
Revenue Revenue for Q2 2025 was $591,000, a decrease year-over-year due to capital market headwinds driven by uncertainty in NIH funding. This was a full impact compared to partial impact in Q1 2025.
Gross Profit Gross profit for Q2 2025 was $351,000, with a gross margin of 59%. The margin includes a 13% benefit from inventory carried at low or no value.
Operating Expenses GAAP total operating expenses for Q2 2025 were $30.5 million, up from $26.8 million in Q2 2024. Adjusted operating expenses were $23.8 million, slightly down from $24.4 million in Q2 2024, reflecting tight cost controls.
Cash and Investments As of June 30, 2025, the company had $214.2 million in cash, cash equivalents, and investments in marketable securities, providing a strong financial position.
Dividend and Interest Income Dividend and interest income for Q2 2025 was $2.3 million, down from $2.9 million in Q2 2024, reflecting lower interest rates and lower invested balances.
Platinum Pro instrument: Launched expanded acquisition options to address capital sales headwinds, allowing customers to acquire instruments without upfront capital. Secured first few customers under this model, driving consumable purchases.
Version 4 sequencing kit: Expected to launch in Q3 2025, increasing proteome coverage and enabling higher multiplexing levels with 24 barcodes.
Version 3 library preparation kit: On track for launch by end of 2025, reducing sample input quantity by 100-fold, enabling broader biological sample processing.
Proteus platform: Development progressing well, with expected launch in H2 2026. Achieved milestones in fluorescent dye development and wafer-scale surface chemistry processing.
PTM detection kits: Feasibility achieved for site-specific peptide-linked PTM detection, transferred to product development for commercialization.
Pharma and biotech market: Doubled funnel of opportunities from 30 to 60 in Q2 2025. Customers in this segment are consistent buyers of consumables.
Revenue: Q2 2025 revenue was $591,000, impacted by NIH funding uncertainties and reduced capital purchases by U.S. academic labs.
Gross margin: 59% in Q2 2025, with variability expected due to commercialization efforts and inventory adjustments.
Operating expenses: Adjusted operating expenses were $23.8 million in Q2 2025, reflecting tight cost controls and funding for innovation.
Cash position: Ended Q2 2025 with $214.2 million in cash and marketable securities, with runway into Q2 2028 after a $50 million capital raise in July.
Installed base growth: Focus on growing installed base to drive consumable sales and scientific validation, leveraging favorable production costs and strong balance sheet.
AI in recognizer design: Utilized AI to accelerate amino acid recognizer development, achieving specifications within one design cycle.
Capital Market Headwinds: The company is facing significant challenges due to uncertainties in NIH funding, which has led to a near halt in capital purchases by U.S. academic labs. This has negatively impacted revenue, particularly from capital sales of new instruments.
Longer Sales Cycles in Pharma and Biotech: While the company has doubled its funnel of opportunities in the pharma and biotech sectors, the longer sales cycles in these markets pose a challenge to immediate revenue generation.
Dependence on Consumable Revenue: The company is constrained by its reliance on consumable revenue, which is limited by the current single instrument acquisition model. This model restricts the number of users who can adopt the technology.
Litigation Costs: The company incurred approximately $3.4 million in expenses related to the Delaware stockholder litigation, which could impact financial performance.
Tariff and Import Risks: Although currently minor, the company is monitoring potential impacts of tariffs on inventory acquisition costs and customer purchases, which could pose future risks.
Uncertain Financial Guidance: Due to the ongoing NIH funding uncertainties and the early stages of new capital acquisition models, the company is unable to provide clear top-line financial guidance, adding to investor uncertainty.
Revenue Expectations: The company is optimistic about growing its customer base using a mix of instrument acquisition options, which is expected to drive consumable revenue. However, the company refrains from providing detailed top-line financial guidance until there is more clarity on the NIH funding environment and the momentum of new acquisition models.
Product Launches: The version 4 sequencing kit is expected to launch during the current quarter, and the version 3 library preparation kit is on track for launch by the end of 2025. The Proteus platform is expected to launch in the second half of 2026, with significant advancements in capabilities.
Market Trends and Opportunities: The company sees long-term market opportunities in proteomics and is optimistic about the potential for growth in pharma and biotech segments, despite current capital market headwinds. The company is also focusing on creating a large installed base of active users to drive long-term value.
Capital Expenditures and Financial Strength: The company has revised its annual estimate for adjusted operating expenses to $98 million or less and expects total cash use to be $95 million or less for 2025. The company anticipates its cash balance, along with recent capital raises, to provide financial runway into the second quarter of 2028.
Technological Advancements: The company is making progress in its innovation roadmap, including AI-based amino acid recognizer design and post-translational modification detection kits, which are expected to enhance research capabilities and system performance.
Dividend and Interest Income: In the second quarter of 2025, dividend and interest income was $2.3 million compared to $2.9 million in the second quarter of 2024. For the six months ended June 30, 2025, it was $4.9 million compared to $6.5 million in the same period in 2024. This reflects lower interest rates year-over-year as well as relatively lower invested balances.
The earnings call presents mixed signals: revenue has decreased, and there are uncertainties in NIH funding, but there is optimism about product launches and market opportunities. The Q&A reveals management's evasiveness on key issues, adding uncertainty. Despite financial constraints, cost controls are evident. Strong financial metrics are offset by weak guidance and lack of clarity, leading to a neutral sentiment.
The earnings call summary and Q&A reveal strong financial performance with an 84% revenue increase and a 58% gross margin. Management is optimistic about growth, especially in Q4, and is implementing flexible sales models to overcome capital constraints. The company is focused on innovation and market expansion, particularly in pharma and biotech. Despite some unclear responses, the overall sentiment is positive, supported by strategic product launches and a solid cash position. The stock price is likely to experience a positive movement in the next two weeks.
The earnings call reveals mixed signals: strong revenue growth and international expansion are positive, but uncertainties in NIH funding and a slowdown in the U.S. academic market are concerning. The Q&A session highlights confidence in the biopharma market and positive feedback on product launches, but unclear responses on tariffs and a dip in dividend income raise caution. With a robust cash position and strategic partnerships, the short-term stock reaction is likely neutral, balancing positive growth against market uncertainties.
The earnings call reveals mixed signals: strong revenue growth and international expansion are positive, but uncertainties in the U.S. academic market and regulatory issues create concerns. The Q&A highlighted management's confidence in partnerships and product launches, yet avoided specifics on tariff impacts. Financials show increased revenue but lower-than-expected results due to market slowdowns. The strong cash position is reassuring, but dividend income decline is negative. Overall, the sentiment balances out to neutral, with no extreme factors to drive significant stock movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
